Amorepacific Corporation

KOSE:A090430 Stock Report

Market Cap: ₩6.8t

Amorepacific Valuation

Is A090430 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A090430 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A090430 (₩110200) is trading below our estimate of fair value (₩181947.53)

Significantly Below Fair Value: A090430 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A090430?

Key metric: As A090430 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A090430. This is calculated by dividing A090430's market cap by their current earnings.
What is A090430's PE Ratio?
PE Ratio11.6x
Earnings₩653.21b
Market Cap₩6.79t

Price to Earnings Ratio vs Peers

How does A090430's PE Ratio compare to its peers?

The above table shows the PE ratio for A090430 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23.1x
A051900 LG H&H
43x25.5%₩5.2t
A002790 AMOREPACIFIC Group
7.8x2.8%₩1.8t
A192820 Cosmax
20.1x27.3%₩1.5t
A278470 APR
21.5x25.7%₩1.9t
A090430 Amorepacific
11.6x-21.7%₩6.8t

Price-To-Earnings vs Peers: A090430 is good value based on its Price-To-Earnings Ratio (11.6x) compared to the peer average (23.1x).

Price to Earnings Ratio vs Industry

How does A090430's PE Ratio compare vs other companies in the KR Personal Products Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
A900120 CXI Healthcare Technology Group
0.8xn/aUS$16.21m
No more companies available in this PE range
A090430 11.6xIndustry Avg. 17.3xNo. of Companies6PE0816243240+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A090430 is good value based on its Price-To-Earnings Ratio (11.6x) compared to the KR Personal Products industry average (17.3x).

Price to Earnings Ratio vs Fair Ratio

What is A090430's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A090430 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11.6x
Fair PE Ratio9.5x

Price-To-Earnings vs Fair Ratio: A090430 is expensive based on its Price-To-Earnings Ratio (11.6x) compared to the estimated Fair Price-To-Earnings Ratio (9.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A090430 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩110,000.00
₩166,931.03
+51.8%
17.5%₩220,000.00₩99,000.00n/a29
Nov ’25₩120,300.00
₩166,931.03
+38.8%
17.5%₩220,000.00₩99,000.00n/a29
Oct ’25₩147,700.00
₩191,833.33
+29.9%
9.4%₩220,000.00₩150,000.00n/a24
Sep ’25₩124,400.00
₩193,500.00
+55.5%
10.3%₩235,000.00₩150,000.00n/a24
Aug ’25₩177,800.00
₩205,625.00
+15.6%
12.0%₩245,000.00₩150,000.00n/a24
Jul ’25₩167,100.00
₩206,666.67
+23.7%
11.7%₩245,000.00₩150,000.00n/a24
Jun ’25₩194,200.00
₩203,750.00
+4.9%
10.5%₩245,000.00₩142,000.00n/a24
May ’25₩169,500.00
₩192,708.33
+13.7%
11.9%₩220,000.00₩142,000.00n/a24
Apr ’25₩129,100.00
₩160,041.67
+24.0%
12.3%₩190,000.00₩102,000.00n/a24
Mar ’25₩119,600.00
₩160,541.67
+34.2%
12.3%₩190,000.00₩102,000.00n/a24
Feb ’25₩119,600.00
₩160,920.00
+34.5%
12.0%₩190,000.00₩102,000.00n/a25
Jan ’25₩145,000.00
₩161,250.00
+11.2%
12.1%₩190,000.00₩102,000.00n/a24
Dec ’24₩128,000.00
₩157,500.00
+23.0%
13.7%₩190,000.00₩102,000.00n/a24
Nov ’24₩134,700.00
₩154,000.00
+14.3%
14.0%₩190,000.00₩102,000.00₩120,300.0023
Oct ’24₩122,000.00
₩138,022.73
+13.1%
14.4%₩160,000.00₩90,000.00₩147,700.0022
Sep ’24₩133,300.00
₩136,273.91
+2.2%
14.3%₩160,000.00₩85,300.00₩124,400.0023
Aug ’24₩113,300.00
₩130,491.30
+15.2%
16.8%₩160,000.00₩80,000.00₩177,800.0023
Jul ’24₩97,600.00
₩143,090.91
+46.6%
20.4%₩180,000.00₩80,000.00₩167,100.0022
Jun ’24₩104,900.00
₩148,681.82
+41.7%
19.3%₩190,000.00₩87,000.00₩194,200.0022
May ’24₩123,300.00
₩155,318.18
+26.0%
17.1%₩190,000.00₩87,000.00₩169,500.0022
Apr ’24₩136,800.00
₩152,772.73
+11.7%
16.3%₩180,000.00₩87,000.00₩129,100.0022
Mar ’24₩138,400.00
₩152,450.00
+10.2%
16.5%₩180,000.00₩87,000.00₩119,600.0020
Feb ’24₩141,400.00
₩148,142.86
+4.8%
17.8%₩180,000.00₩75,000.00₩119,600.0021
Jan ’24₩137,500.00
₩135,550.00
-1.4%
19.7%₩170,000.00₩75,000.00₩145,000.0020
Dec ’23₩128,000.00
₩131,850.00
+3.0%
21.0%₩170,000.00₩75,000.00₩128,000.0020
Nov ’23₩96,700.00
₩131,444.44
+35.9%
24.5%₩180,000.00₩70,000.00₩134,700.0018

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

NeoPharm

₩193.5b

Engages in the manufacturing and sale of skin care products in South Korea.

A092730

₩11,840.00

7D

-9.1%

1Y

3.0%

NOVAREXLtd

₩136.0b

Manufactures, wholesales, and retails health and functional foods in South Korea and internationally.

A194700

₩7,650.00

7D

-18.7%

1Y

-31.5%

Cosmecca Korea

₩600.2b

Engages in the research and development, manufacture, and sale of skincare products in South Korea and internationally.

A241710

₩53,900.00

7D

-13.6%

1Y

44.3%